Urethral Stricture Treatment Market to Make Great Impact in Near Future by 2026 | C. R. Bard, Inc., Amecath, Uromed, MedNova, Allium Medical, Surgimedik, Cook Medical Inc., Mednova, Taewoong Medical, Teleflex Incorporated,

According to the National Centers for Biotechnology & Information (NCBI), urethral stricture is a common disease with prevalence of over 400 per 100,000 population among males in year 2016 globally. According to the Cancer Research UK, in males in the U.K., prostate cancer is the most common cancer with around 47,200 new cases registered in 2015. Moreover, the incidence rates of prostate cancer are projected to rise by 12% between 2014 and 2035, to 233 cases per 100,000 males by 2035 in the U.K., as per Cancer Research UK. High catheter associated urinary tract infection (CAUTI) rates of 6.8 per 1000 device days were observed in the UAE medical units in March 2015.

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2381

Moreover, advancements in development of therapies for treating urethral strictures is driving growth of the urethral stricture treatment market. For instance, a Germany-based company, MukoCell GmbH developed a tissue engineering-based product called MukoCell, which is used for repair of urethral strictures and hypospadias. This product is an alternative to conventional transplantation with native buccal mucosa.

However, high cost of surgical procedures and high rate of complications are some of the major factors restraining growth of the global urethral stricture treatment market. According to Healthcare Cost and Utilization Project (HCUP) 2016, the average cost of male urethroplasty can range between US$ 5,677–US$ 10,000 with an average increase of US$ 616 per year in the U.S.

Increasing cases of prostate cancers, injuries, and medical conditions requiring urethral stents, dilators, and catheters is one of the major factors for rise in urethral stricture cases, which in turn is driving growth of the urethral stricture treatment market.

Major players operating in the global urethral stricture treatment market include C. R. Bard, Inc., Amecath, Uromed, MedNova, Allium Medical, Surgimedik, Cook Medical Inc., Mednova, Taewoong Medical, Teleflex Incorporated, B. Braun Holding GmbH & Co. KG, Urotech, Coloplast Ltd, Boston Scientific Corporation, and Pnn Medical A/S.

Key players are focusing on expanding their product portfolio, in order to retain dominant position in the market. For instance, Allium Medical, which manufactures and markets minimally invasive products, entered into the market with its product, Allium’s Ureteral Stents, which has some unique composition and better bio-compatibility.

Get Exclusive Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2381

Urethral Stricture Treatment Market - Taxonomy

On the basis of type, the global urethral stricture treatment market is segmented into:

Posterior Urethral Stricture
Anterior Urethral Stricture
On the basis of cause, the global urethral stricture treatment market is segmented into:

Iatrogenic
Idiopathic
Infection-induced
Trauma
Others
On the basis of diagnosis, the global urethral stricture treatment market is segmented into:

Ultrasound
Urinalysis
Uri flow test
Pelvic ultrasound
Cystoscopy
Others
On the basis of treatment, the global urethral stricture treatment market is segmented into:

Urethral Dilation
Direct Vision Internal Urethrotomy (DVIU)
Urethroplasty
Others
On the basis of geography, the global urethral stricture treatment market is segmented into:

North America
Latin America
Europe
Asia Pacific
Middle East
Africa

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.